Carregant...
Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoin...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley-Blackwell
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313266/ https://ncbi.nlm.nih.gov/pubmed/27534574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0189 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|